Bevacizumab for Central Retinal Vein Occlusion Study

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Central retinal vein occlusion is a leading cause of severe visual impairment. Until now, no treatment has been available to improve visual acuity. The present study intends to investigate if intravitreal bevacizumab can improve visual acuity as compared to sham-treated control patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Anders Kvanta
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• CRVO with duration < 6 months

• Visual acuity of 20/800 to 20/50

Exclusion Criteria:

• CRVO with duration of > 6 months

• previous treatment with anti-angiogenic drugs